Abstracts tagged "Myositis"

Abstract Number: 2069 • ACR Convergence 2024
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Lovely Kumari¹, VISHNU KONERU², subin Philip¹, sai Kumar Dunga³, Mamatha gorijavulu⁴, Aishwarya Gopal⁵, Christina Mariaselvam⁶, Molly Thabah⁷, Vir Singh Negi⁸ and Chengappa Kavadichanda⁹, ¹JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, ²JIPMER,PUDUCHERRY, PUDUCHERRY, India, ³JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, ⁴JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶JIPMER, Puducherry, Puducherry, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁸AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, ⁹Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India
Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
Abstract Number: 2305 • ACR Convergence 2024
Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease
Marie ROBERT¹, Yann Nguyen², Yurdagül Uzunhan³, Benjamin Terrier⁴, Yves Allenbach⁵, Alain Meyer⁶, Jacques-Eric Gottenberg⁷, JEROME HADJADJ⁸, Zahir Amoura⁹, ARNAUD HOT¹⁰, Eléonore Bettacchioli¹¹, Elisabeth Aslangul¹², Rakiba Belkhir¹³, Frederic Desmoulins¹⁴, Elisabeth Bergé¹⁴, Pascale Chrétien¹⁵, Pascale Roland-Nicaise¹⁶, Claire Goulvestre¹⁷, Jean-Luc Charuel¹⁸, Benoit Nespola¹⁹, Nicole Fabien²⁰, Eric Ballot²¹, Gaetane Nocturne¹⁴, Xavier Mariette¹⁴, Samuel Bitoun¹ and Raphaele Seror²², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Service de Médecine interne et immunologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸Service de Médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ⁹French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, ¹⁰Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ¹¹Service de Rhumatologie, CHU de Brest, Brest, France, ¹²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ¹³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ¹⁴Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁵Laboratoire d'immunologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, France, ¹⁶Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France, ¹⁷Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ¹⁸Laboratoire d'immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ¹⁹Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²⁰Laboratoire d'immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France, ²¹Laboratoire d'immunologie, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ²²Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France
Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease characterized by a wide range of symptoms, and 30% to 60% of patients developed systemic manifestations. The…
Abstract Number: 0325 • ACR Convergence 2024
The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Jerapas Thongpiya¹, Pojsakorn Danpanichkul¹ and Yanint Raksadawan³, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Yan Zhang¹, Brittany Ross¹, Diana Galvan¹, Yanjie Bao¹, Daiki Matsuda¹, Shaun Grosskurth¹, Iago Pinal-Fernandez², Maria Casal-Dominguez³, Gregor Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian Bot¹, Andrew Mammen² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²NIH, Bethesda, MD, ³NIH, Bathesda, MD
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
Abstract Number: 1156 • ACR Convergence 2024
Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies
Didem Saygin¹, Juan Schmukler², Kristin Wipfler³, Christopher G McKennan⁴, Jiaxuan Duan⁴, Kaleb Michaud⁵ and Yvonne Lee⁶, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Division of Rheumatology, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Pittsburgh, Department of Statistics, Pittsburgh, PA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Northwestern University, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is the prototypical central pain disorder that can be associated with rheumatic conditions such as rheumatoid arthritis, Sjogren’s disease and lupus. Patients…
Abstract Number: 1588 • ACR Convergence 2024
Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
Robert Fairchild¹, Diane Mar², Mariani Deluna³, Henry Guo³, David Fiorentino⁴ and Lorinda Chung⁵, ¹Stanford University, San Francisco, CA, ²VA Palo Alto / Stanford, Palo Alto, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford University, Menlo Park, CA, ⁵Stanford University, Woodside, CA
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue disease (CTD) with a high prevalence in SSc and inflammatory myopathy (IM). Early…
Abstract Number: 2070 • ACR Convergence 2024
Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Margherita Giannini¹, Anne-Laure Charles², Julien Blaess³, Rose-Marie Javier⁴, Bernard Geny⁵ and Alain Meyer⁶, ¹UR3072, Physiology Department, University Hospital of Strasbourg, Strasbourg, France, ²UR3072, University of Strasbourg, Strasbourg, France, ³Physiology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁴Rheumatology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁵UR3072, Physiology Department, University Hospital of StrasbourgUniversity Hospital of Strasbourg, STRASBOURG, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In inflammatory myopathies (IM), although several treatments effectively control disease activity, a high proportion of patients display sustained disability (damage). Damage might be reversed…
Abstract Number: 2392 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Güllü Sandal Uzun¹ and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and idiopathic inflammatory myositis (IIM) are chronic, potentially severe autoimmune diseases, that may affect many organs/ systems. In this study, we…
Abstract Number: 0326 • ACR Convergence 2024
Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)
Maha Almackenzie¹, Anushka Aggarwal², shiri keret³, shreya Sriram⁴, Tanya Chandra⁵, Raisa Silva⁶, Eugenia Gkiaouraki⁴, Siamak Mogahadam⁷, Chester Oddis⁷ and Rohit Aggarwal⁸, ¹Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, ²Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, ³Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: There are six core set measures (CSMs) of disease activity in patients with idiopathic inflammatory myopathies (IIM). However, there is limited data on their…
Abstract Number: 0901 • ACR Convergence 2024
Intergenic Alu Elements Are Uniquely Expressed in Dermatomyositis and Correlate with Interferon Stimulated Genes
Rayan Najjar¹, Andrew Mammen² and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²NIH, Bethesda, MD
Background/Purpose: As genes constitute < 2% of our genomes, there is a need to explore potential roles of other genomic elements in autoimmune disease. We…
Abstract Number: 1157 • ACR Convergence 2024
Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases
Shane Cameron, Liam O'Neil, Annaliese Tisseverasinghe and Christine Peschken, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatic diseases such as autoimmune myopathy (AIM), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) confer an increased risk for atherosclerotic disease. The 3-hydroxy-3-methylglutaryl-coenzyme…
Abstract Number: 1645 • ACR Convergence 2024
Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells
Maria Casal-Dominguez¹, Iago Pinal-Fernandez², Sandra Muñoz-braceras³, Corinna preuße⁴, katherine Pak¹, Jiram Torres Ruiz⁵, Jon Musai¹, Stefania Dell'Orso⁶, Faiza Naz⁶, Shamima Islam², Gusatavo Gutierrez-Cruz², Albert Selva-O’Callaghan⁷, jose milisenda⁸, Werner Stenzel⁹ and Andrew Mammen², ¹National Institutes of health, Bethesda, MD, ²NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁷Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁸Hospital Clinic de Barcelona, Barcelona, Spain, ⁹Charite University, Berlin, Germany
Background/Purpose: Antisynthetase syndrome (AS) is type of myositis characterized by autoantibodies targeting aminoacyl-transfer tRNA synthetases (aaRSs), the enzymes responsible for loading the appropriate amino acid…
Abstract Number: 2071 • ACR Convergence 2024
Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
praggya yaadav¹, Maria Rosa Pellico², Anne-Marie Russell³, Aviya Lanis⁴, Elena Nikiphorou⁵, Ioannis Parodis⁶, Sreoshy Saha⁷, Manali Sarkar⁸, Jasmine Parihar⁹, Laura Andreoli¹⁰, Vikas Agarwal¹¹ and Latika Gupta¹², and COVAD Steering Committee, COVAD Study Group, ¹Maharashtra Institute of Medical Sciences and Research, Latur, Aurangabad, India, ²University of Milan, Milan, Italy, ³Birmingham Regional Interstitial Lung Disease Service, University Hospitals Birmingham NHS Trust and Faculty of Life Sciences, University of Exeter, Exeter, UK, Birmingham, United Kingdom, ⁴Seattle Children's Hospital, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁷Mymensingh Medical College, Mymensingh, Bangladesh, ⁸MGM Medical College, Navi Mumbai, Maharashtra, India, ⁹All India Institute of Medical Science, New Delhi, Delhi, India, ¹⁰University of Brescia, Brescia, Italy, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹²Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
Background/Purpose: Self-efficacy is crucial for chronic disease management. Given the increasing prevalence of chronic diseases, encouraging patients to actively manage their disease may be an…
Abstract Number: 2406 • ACR Convergence 2024
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
Sai Yasaswini Kommaraju¹, Liza Rajasekhar², Ashish J Mathew³, Vineeta Shobha⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Able Lawrence⁷, Bidyut Das⁸, Manish Rathi⁹, Ranjan Gupta¹⁰, Avinash Jain¹¹ and Amita Aggarwal¹², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ³Christian Medical College, Vellore, Tamil Nadu, India, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁸SCB Medical College, Cuttack, Orissa, India, ⁹Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹⁰All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹¹Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) has a significant impact on morbidity associated with SLE. However, the prevalence of NPSLE has been reported variably based…
Abstract Number: 0329 • ACR Convergence 2024
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
Raisa Silva¹, Manuel Carpio Tumba², Sneha Gupta³, Latika Gupta⁴, Pedro M Machado⁵, Julie Paik⁶, Diana Louden⁷, Lesley Ann Saketkoo⁸, Sebastian E. Sattui² and Didem Saygin⁹, ¹Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, ⁴Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, ⁵Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Washington Libraries, Seattle, WA, ⁸New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ⁹Rush University Medical Center, Chicago, IL
Background/Purpose: The growing number of randomized clinical trials (RCTs) in idiopathic inflammatory myopathies (IIMs) points to a promising future for therapeutics in IIM. Adequate representation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.